Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFRm Advanced Non-Small Cell Lung Cancer × 1 year × Clear all
NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Daiichi Sankyo

Approved for marketing
Thoracic

EGFRm Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡